Wei Sang

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 18

Top Venues

Nature communications

Annals of hematology

Cancer medicine

Leukemia & lymphoma

Nanjing Medical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Nanjing Medical University Sep 01 2011 - Jul 01 2015

China

PHD :: hematology

Publications

Zaixiang Tan, Qing Zhang, Ying Wang, Yubo Wang, Shuo Zhang, Xing Xing, Hui Liu, Ziyuan Shen, Wei Sang
Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma. Annals of hematology 103 (8) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Zaixiang Tan, Qing Zhang, Ying Wang, Yubo Wang, Shuo Zhang, Xing Xing, Hui Liu, Ziyuan Shen, Wei Sang
Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma. Annals of hematology 103 (8) (2024)
Zaixiang Tan, Qing Zhang, Ying Wang, Yubo Wang, Shuo Zhang, Xing Xing, Hui Liu, Ziyuan Shen, Wei Sang
Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma. Annals of hematology 103 (8) (2024)
Zaixiang Tan, Qing Zhang, Ying Wang, Yubo Wang, Shuo Zhang, Xing Xing, Hui Liu, Ziyuan Shen, Wei Sang
Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma. Annals of hematology (2024)
Ying Wang, Ziyuan Shen, Chenlu He, Xing Xing, Zaixiang Tan, Wei Sang
Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021. Blood cancer journal 14 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ziyuan Shen, Xicheng Chen, Cai Sun, Tianyi Lu, Yuye Shi, Hao Zhang, Jingjing Ye, Ling Wang, Taigang Zhu, Yuqing Miao, Xudong Zhang, Liang Wang, Guoqi Cai, Wei Sang
Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma. Cancer medicine (2023)
Xiao-Tian Zhang, Xue Wang, Jiang Cao, Wei Chen, Kun-Ming Qi, Na Qi, Fei Liang, Xue-Yan Dong, Guo-Feng Tang, De-Peng Li, Wei Sang, Zhen-Yu Li, Hai Cheng, Kai-Lin Xu
Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience. Hematology (Amsterdam, Netherlands) 26 (1) (2022)
Yuekun Qi, Mingfeng Zhao, Yongxian Hu, Ying Wang, Ping Li, Jiang Cao, Ming Shi, Jiaqi Tan, Meng Zhang, Xia Xiao, Jieyun Xia, Sha Ma, Jianlin Qiao, Zhiling Yan, Hujun Li, Bin Pan, Wei Sang, Depeng Li, Zhenyu Li, Jianfeng Zhou, He Huang, Aibin Liang, Junnian Zheng, Kailin Xu
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood 139 (23) (2022)
Sha Ma, Bingpei Zhang, Tianyi Lu, Dashan Li, Tianci Li, Ziyuan Shen, Chenlu He, Ying Wang, Bingzong Li, Hao Zhang, Weiying Gu, Chunling Wang, Jingjing Ye, Taigang Zhu, Yuqing Miao, Ling Wang, Shuiping Huang, Qinhua Liu, Wei Sang, null null
Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group. Cancer 128 (19) (2022)
Ziyuan Shen, Shuo Zhang, Yaxue Jiao, Yuye Shi, Hao Zhang, Fei Wang, Ling Wang, Taigang Zhu, Yuqing Miao, Wei Sang, Guoqi Cai, Working Group Huaihai Lymphoma
LASSO Model Better Predicted the Prognosis of DLBCL than Random Forest Model: A Retrospective Multicenter Analysis of HHLWG. Journal of oncology 2022 (2022)
Ziyuan Shen, Lingling Hu, Mingkang Yao, Chenlu He, Qinhua Liu, Fei Wang, Weiying Gu, Ying Wang, Manyu Dong, Taigang Zhu, Ting Yin, Fei Li, Yingliang Jin, Shuiping Huang, Hao Zhang, Wei Sang, null null
Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group. International journal of cancer 150 (2) (2021)
Xin-Xin Cao, Shu-Hua Yi, Zhong-Xing Jiang, Jing-Song He, Wei Yang, Juan Du, Chun-Yan Sun, Yu Wu, Wen-Ming Chen, Xiao-Jun Liu, Bing-Zong Li, Chun-Rui Li, Wei Sang, Qin-Hua Liu, Xiao-Xia Chu, Fei Li, Ou Bai, Min Mao, Rong Fu, Wei Wang, Li-Hong Liu, Lu-Qun Wang, Yu-Jun Dong, Jun Luo, Zhen-Ling Li, Yong-Qiang Wei, Qi-Ke Zhang, Jing Liu, Kai-Yang Ding, Liang Zou, Bi-Yun Chen, Luo-Ming Hua, Hong-Mei Jing, Juan He, Liang Wang, Jian Li, Lu-Gui Qiu
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. Leukemia & lymphoma 62 (11) (2021)
Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng, Kailin Xu
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer medicine 9 (16) (2020)

Wei Sang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Wei Sang